CTKB - Cytek Biosciences, Inc. Stock Price, Fair Value and News

$6.14+0.01 (+0.16%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CTKB Price Action

Last 7 days

-9.4%

Last 30 days

19.5%

Last 90 days

17.4%

Trailing 12 Months

-0.8%

CTKB RSI Chart

CTKB Valuation

Market Cap

790.9M

Price/Earnings (Trailing)

-77.85

Price/Sales (Trailing)

3.93

EV/EBITDA

-127.71

Price/Free Cashflow

27.5

CTKB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CTKB Fundamentals

CTKB Revenue

Revenue (TTM)

201.2M

Rev. Growth (Yr)

7.29%

Rev. Growth (Qtr)

10.47%

CTKB Earnings

Earnings (TTM)

-10.2M

Earnings Growth (Yr)

114.58%

Earnings Growth (Qtr)

109.02%

CTKB Profitability

EBT Margin

-5.92%

Return on Equity

-2.64%

Return on Assets

-2.07%

Free Cashflow Yield

3.64%

CTKB Investor Care

Buy Backs (1Y)

4.97%

CTKB Alerts

Big jump in Earnings (Y/Y)

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	200.8M	197.7M	201.2M	0
2023	166.1M	175.6M	183.1M	193.0M
2022	138.7M	148.5M	154.6M	164.0M
2021	101.6M	110.4M	119.2M	128.0M
2020	0	0	0	92.8M

Get all data in R, Python etc through our Historical Stock Data APIs

About Cytek Biosciences, Inc.

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

CEO	Dr. Wenbin Jiang Ph.D.
WEBSITE	https://cytekbio.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	699

Cytek Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Cytek Biosciences, Inc.? What does CTKB stand for in stocks?

CTKB is the stock ticker symbol of Cytek Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cytek Biosciences, Inc. (CTKB)?

As of Wed Nov 20 2024, market cap of Cytek Biosciences, Inc. is 790.9 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CTKB stock?

You can check CTKB's fair value in chart for subscribers.

Is Cytek Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether CTKB is over valued or under valued. Whether Cytek Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Cytek Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CTKB.

What is Cytek Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, CTKB's PE ratio (Price to Earnings) is -77.85 and Price to Sales (PS) ratio is 3.93. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CTKB PE ratio will change depending on the future growth rate expectations of investors.